Maravai LifeSciences (MRVI) announced its acquisition of intellectual property and relevant assets from Molecular Assemblies, or MAI. The acquisition will expand Maravai and TriLink BioTechnologies’ ability to enable customers to develop next-generation mRNA and CRISPR nucleic acid-based therapies.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai LifeSciences Restructures Leadership Amid Revenue Update
- Maravai sees 2024 revenue at midpoint of $255M-$265M range
- Maravai Lifesciences initiated with a Neutral at Guggenheim
- Maravai Lifesciences chairman Carl Hull to retire, R. Andrew Eckert to succeed
- Maravai LifeSciences Appoints New Chairman Amid Leadership Transition